Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers.

John C Reed1, Shinichi Kitada, Youngsoo Kim

  • 1Burnham Institute, La Jolla, CA 92037, USA.

Seminars in Oncology
|February 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment.

Blood advances·2023
Same author

K63 ubiquitination in immune signaling.

Trends in immunology·2022
Same author

Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model.

Experimental hematology & oncology·2021
Same author

Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.

Therapeutic innovation & regulatory science·2021
Same author

ASCLD statement on volume of untested sexual assault evidence kits.

Forensic science international. Synergy·2021
Same author

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Blood advances·2020

Low-grade B-cell malignancies like chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) often result from apoptosis defects, leading to chemoresistance. Novel apoptosis modulators offer potential for more effective cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Low-grade B-cell malignancies, including chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), are significant causes of cancer mortality.
  • These cancers are characterized by defects in programmed cell death (apoptosis), leading to B-lymphocyte accumulation rather than rapid proliferation.
  • Impaired apoptosis contributes to chemoresistance and immune evasion in neoplastic cells.

Purpose of the Study:

  • To explore the role of apoptosis defects in the pathogenesis of low-grade B-cell malignancies.
  • To review current and potential therapeutic strategies targeting apoptosis pathways.
  • To identify novel biological agents and small molecules that modulate apoptosis for cancer treatment.

Main Methods:

  • Review of scientific literature on apoptosis pathways in B-cell malignancies.

Related Experiment Videos

  • Analysis of mechanisms of action for biological response modifiers.
  • Discussion of potential therapeutic strategies based on apoptosis modulation.

    • Main Results:

    • Defects in apoptosis are a primary mechanism driving the development and progression of CLL and FL.
    • Several classes of agents, including monoclonal antibodies (e.g., rituximab), cytokines (e.g., TRAIL), and small-molecule kinase inhibitors, show promise in modulating apoptosis.
    • These agents have the potential to re-sensitize cancer cells to therapy or induce cell death.

    Conclusions:

    • Targeting apoptosis pathways presents a promising strategy for developing more effective and less toxic therapies for CLL, FL, and other malignancies.
    • Understanding the molecular mechanisms of apoptosis modulation is crucial for advancing cancer treatment.
    • Further research into apoptosis modulators could lead to improved patient outcomes.